Takeda has killed off a late stage programme assessing the potential of alisertib in lymphoma after interim analysis failed to show any benefit in progression-free survival.

Alisertib (MLN8237), acquired by the Japanese drugmaker through its acquisition of Millennium Pharmaceuticals back in 2008, is a kinase inhibitor that interferes with cancer cell division, which was being developed for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

Though demise of the programme will undoubtedly hurt, the firm said it is pushing on with an ongoing Phase II trial evaluating the drug in small cell lung cancer and will evaluate its potential use in other oncology indications going forward.